Rubicon Signs Agreement with Foothill Scientific
Category : Corporate
Lake Forest, CA (January 25th, 2017) – Rubicon Biotechnology and Foothill Scientific Associates (FSA) announce an agreement in which Rubicon will contract with Foothill Scientific Associates for services related to government grants, contracting, product development and business development. Foothill Scientific Associates (FSA) is a network of professionals in the areas of Drug Development, Program Management, Engineering, Human Resource and Contract Administration. The group is composed of Industry, Academic, and Federal program veterans able to move programs and products forward efficiently and cost-effectively. FSA has special expertise in business process management which provides the operational foundation to these activities. The groups key practice areas are: vaccine and biologics development, medical device product development, Federal contracting, and finance and capital raising. Mark Logomasini, MBA, PMP is a Sr. Partner of FSA and is an experienced life sciences executive with a successful 25+ year track record in drug development and medical devices. Most recently he was the President/CEO of Bioject Medical Technologies, acquired by Inovio Pharmaceuticals in 2016. Prior to that he was the head of Federal Programs for Sigma-Aldrich’s SAFC contract service division. He moved into that position when Sigma-Aldrich acquired Molecular Medicine BioServices in 2007, where he was a co-founder and CFO/VP Business Development.
About Rubicon Biotechnology
Rubicon Biotechnology is a privately held biotechnology company that develops targeted, life-saving technologies in the areas of defense countermeasures, cardiology, neurology and oncology. Rubicon has in-licensed two platform technologies for drug development. The first is “Antibody Mediated Transduction of Heat Shock Proteins into Living Cells” from the Veterans Administration. This technology delivers heat shock protein, a key protein which saves injured cells that suffer hypoxic and oxidative stresses that unfortunately occur following common tissue injuries, such as heart attack, stroke and traumatic brain injury. The second technology, “Modified Non-Internalizing A5 Variants,” licensed from MosaMedix B.V., delivers immunostimulants to tumors in order to enhance the immune system’s ability to fight cancer. With support from several SBIR and CounterACT grants, and in collaboration with major institutions in the U.S., Rubicon is developing these targeted therapies with the goal of improving health outcomes and saving lives.